Improving attrition rates in Ebola virus drug discovery

Sanja Glisic, Slobodan Paessler, Nevena Veljkovic, Vladimir R. Perovic, Jelena Prljic, Veljko Veljkovic

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used.Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs.Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro-and in silico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.

Original languageEnglish (US)
Pages (from-to)1025-1032
Number of pages8
JournalExpert Opinion on Drug Discovery
Volume10
Issue number9
DOIs
StatePublished - Sep 2 2015

Fingerprint

Ebolavirus
Drug Discovery
Ebola Hemorrhagic Fever
Disease Outbreaks
Pharmaceutical Preparations
Therapeutics
Drug Repositioning
Endemic Diseases
Western Africa
Expert Testimony
Computer Simulation

Keywords

  • drug discovery
  • Ebola virus
  • virtual screening

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Glisic, S., Paessler, S., Veljkovic, N., Perovic, V. R., Prljic, J., & Veljkovic, V. (2015). Improving attrition rates in Ebola virus drug discovery. Expert Opinion on Drug Discovery, 10(9), 1025-1032. https://doi.org/10.1517/17460441.2015.1062872

Improving attrition rates in Ebola virus drug discovery. / Glisic, Sanja; Paessler, Slobodan; Veljkovic, Nevena; Perovic, Vladimir R.; Prljic, Jelena; Veljkovic, Veljko.

In: Expert Opinion on Drug Discovery, Vol. 10, No. 9, 02.09.2015, p. 1025-1032.

Research output: Contribution to journalArticle

Glisic, S, Paessler, S, Veljkovic, N, Perovic, VR, Prljic, J & Veljkovic, V 2015, 'Improving attrition rates in Ebola virus drug discovery', Expert Opinion on Drug Discovery, vol. 10, no. 9, pp. 1025-1032. https://doi.org/10.1517/17460441.2015.1062872
Glisic, Sanja ; Paessler, Slobodan ; Veljkovic, Nevena ; Perovic, Vladimir R. ; Prljic, Jelena ; Veljkovic, Veljko. / Improving attrition rates in Ebola virus drug discovery. In: Expert Opinion on Drug Discovery. 2015 ; Vol. 10, No. 9. pp. 1025-1032.
@article{6fe92b00319640d780114debb96276b2,
title = "Improving attrition rates in Ebola virus drug discovery",
abstract = "Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used.Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs.Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro-and in silico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.",
keywords = "drug discovery, Ebola virus, virtual screening",
author = "Sanja Glisic and Slobodan Paessler and Nevena Veljkovic and Perovic, {Vladimir R.} and Jelena Prljic and Veljko Veljkovic",
year = "2015",
month = "9",
day = "2",
doi = "10.1517/17460441.2015.1062872",
language = "English (US)",
volume = "10",
pages = "1025--1032",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Improving attrition rates in Ebola virus drug discovery

AU - Glisic, Sanja

AU - Paessler, Slobodan

AU - Veljkovic, Nevena

AU - Perovic, Vladimir R.

AU - Prljic, Jelena

AU - Veljkovic, Veljko

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used.Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs.Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro-and in silico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.

AB - Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used.Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs.Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro-and in silico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.

KW - drug discovery

KW - Ebola virus

KW - virtual screening

UR - http://www.scopus.com/inward/record.url?scp=84938943006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938943006&partnerID=8YFLogxK

U2 - 10.1517/17460441.2015.1062872

DO - 10.1517/17460441.2015.1062872

M3 - Article

VL - 10

SP - 1025

EP - 1032

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 9

ER -